(Q28343761)

2

0 references

A Aberg-Wistedt

3

0 references

B Hallén

4

0 references

L Bertilsson

British Journal of Clinical Pharmacology

5

0 references

language of work or name

English

0 references

publication date

October 1999

0 references

published in

0 references

volume

48

0 references

issue

4

0 references

page(s)

553-63

0 references

cites work

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

A preliminary study of serotonergic antidepressants in treatment of dysthymia

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014382

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine

2 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00051.X

Prevalence of urinary incontinence.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00051.X

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.1365-2125.1999.00051.X

Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial

21 January 2018

1 reference

12 December 2020

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

12 December 2020

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

12 December 2020

Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

1 reference

12 December 2020

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

12 December 2020

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

12 December 2020

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry

1 reference

12 December 2020

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

12 December 2020

Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes

1 reference

12 December 2020

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

12 December 2020

Serum protein binding of tolterodine and its major metabolites in humans and several animal species

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity

1 reference

12 December 2020